{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012057","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.031913+00:00","generated_at":"2026-05-31T09:40:28.424616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fortress Biotech Q2 net loss $13.3M; pauses preferred dividend; two PDUFA dates in Q4 2024","bullets":["Q2 2024 net revenue $14.9M (dermatology) vs $17.4M Q2 2023; net loss attributable to common $13.3M ($0.73/sh) vs $26.9M ($3.65/sh).","Cash and equivalents $76.2M at June 30, down from $80.9M at Dec 31, 2023; $38.2M attributable to Fortress/private subs.","Board paused Series A Preferred Stock (9.375%) dividends indefinitely, deferring ~$0.7M/month; new Oaktree loan $35M (up to $50M) repaid prior $50M, net paydown $15M.","FDA PDUFA goal dates: DFD-29 for rosacea Nov 4, 2024; cosibelimab for cSCC Dec 28, 2024 – potential approvals in Q4.","Subsidiary Urica transferred dotinurad rights to Crystalys for 35% equity and 3% royalty; clinical trials ongoing for AJ201 (SBMA) and Triplex (CMV)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012057","json":"https://secwatch.observer/filing/0001558370-24-012057.json","markdown":"https://secwatch.observer/filing/0001558370-24-012057.md","text":"https://secwatch.observer/filing/0001558370-24-012057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837024012057/0001558370-24-012057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837024012057/fbio-20240813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:40:28.424616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}